## 

Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. *Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.* 

# Comparative Study of Techniques in the Diagnosis of Mycoplasma Pneumonia among the Patients of Respiratory Tract Infections in Northern Indian Population Dr. Abhineet Mehrotra<sup>1</sup> <sup>1</sup> Geetanjaly Medical College *Received: 12 December 2014 Accepted: 2 January 2015 Published: 15 January 2015*

#### 8 Abstract

17

Background: In the present study an attempt was made to compare the different diagnosis of
mycoplasma pneumonia among the patients of respiratory tract infections in northern Indian
population. Commonly used techniques in the diagnosis of mycoplasma pneumonia are
culture, serology and PCR and different studies assure the different sensitivity and specificity.
In the present study author also aim to find the common risk factors of mycoplasma
pneumonia. Material Methods: The present study was undertaken at Career Institute of
Medical Science, Lucknow. The total number of study subjects were 193. The total number of

 $_{16}$  male subjects were 115 (59.6

18 Index terms— mycoplasma pneumonia, culture, serology,

I. Introduction ycoplasmas (mushroom form) are eubacteria included within the class Mollicutes (from latin 19 mollis = "soft," cutis = "skin"), which comprises the smallest and simplest self-replicating, pleotrophic bacteria 20 that lack cells wall thus, betalactam antibiotics, such as penicillin and cephalosporins, are ineffective. The name 21 Mycoplasma, from the Greek ?????, mykes (fungus) and ??????, plasma (formed), was first used by Albert 22 Bernhard Frank in 1889 1. Mycoplasmas are primarily mucosal pathogens, living a parasitic existence in close 23 24 association with epithelial cells of their host, usually in the respiratory or urogenital tracts. M. pneumoniae 25 exclusively parasitizes humans, whereas some of the other human mycoplasmas have also been recovered from nonhuman primates 2. Mycoplasma pneumoniae is an important cause of respiratory tract infection 26 and is increasingly being associated with other diseases such as asthma and extra-pulmonary complications. 27 Considerable cross-reactivity is known to exist between the whole cell antigens used in the commercial serological 28 testing assays. Usually, mycoplasma infection is a mild illness characterized by fever, cough, bronchitis, sore 29 throat, and headache. In very rare cases, mycoplasma can cause serious illness such as encephalitis (an 30 inflammation of the brain) or meningitis (inflammation of the lining of the brain and spinal cord). 31

As the diagnosis the clinical symptommatology of a mycoplasma infection does not show pathogenspecific 32 characteristics, the diagnostic differentiation from other pathogens such as viruses and gram-positive bacteria is 33 decisive for appropriate therapy 3. The diagnosis can be based on direct detection and serology. Detection of the 34 35 pathogen has been regarded as efficient diagnosis at acute, early stages of disease. Isolation of the pathogen by 36 culture has been considered the reference method. However, it is too insensitive and time-consuming (6-14 days). 37 A good quality pathogen DNA detection system (PCR) is not yet commercially available. To date, serology has been considered the method of choice for diagnosis of infections. The complement fixation test (CFT) represents 38 the classic antibody detection. The CFT cannot discriminate between antibody isotypes. Agglutination tests 39 cannot discriminate between antibody classes either. Both test systems detect mainly the IgM antibody response. 40 In reinfections both CFT and agglutination tests provide predominantly negative results. Nevertheless these test 41 systems currently dominate the ELISA technology 4. By using ELISA, IgG, IgA, and IgM, antibodies can be 42 differentiated. The crucial factor for a specific and sensitive ELISA is the antigen. 5 In the present study we try 43

#### 4 B) SAMPLE SIZE CALCULATION

44 to evaluate the effective method in the diagnosis of mycoplasma pneumonia among three techniques i.e. Serology,

45 Culture & PCR and an attempt was made to explore the socio demographic and clinical characteristics.

#### <sup>46</sup> 1 II. Material & Methods

The present study was undertaken at Career Institute of Medical Science, Lucknow. The total number of study subjects were 286. The total number of male subjects were 115 (59.6 %) while 78 (40.4 %) were females. The present study protocol was approved by institutional ethical committee.

#### <sup>50</sup> 2 a) Culture, Serology and PCR

The expectorated sputum (throat swabs) and blood was collected from all patients. The M. pneumoniae standard 51 strain was revived according to ATCC (American Type Culture Collection) 15531? guidelines (www.atcc.org) 52 which is commercially available in market. In brief, the lyophilized culture was resuspended in 6 ml pleropnemonia 53 like organism (PPLO) broth. A single drop was used to inoculate PPLO agar; 3 ml suspension was used to prepare 54 glycerol stocks and stored at -70°C. The remaining 3ml suspension was incubated at 37°C and 5 per cent CO2 55 incubator till growth was observed with change in color from red to yellow. Mycoplasma pneumoniae strains 56 are very slow growing and produce a very light turbidity. Growth in broth is best observed after 10 to 14 57 days of incubation. Usually it takes at least seven days for the first tubes to start showing growth. Growth is 58 easily recognized by an indicator change from red to orange to yellow. The cells are best transferred when the 59 medium is orange. After medium changes to yellow, cells have started to die. All the patients whose culture was 60 found to be positive were taken for further consideration. The patients having positive culture were marked and 61 further followed for serology. Only serum part which was separated from whole blood of those whose culture was 62 positive. Serum was stored at -20 o C till assayed. ELISA (Enzyme-Linked Immunosorbent Assay) kit is used for 63 64 the accurate qualitative measurement of IgM class antibodies against Mycoplasma pneumoniae in Human serum 65 and plasma. The clinical measurements were recorded. After serological test those patients were again used for follow up (for the purpose of PCR) whose culture as well as serology was found to be positive.as well as all other 66 samples of culture and serology negative were also processed for PCR. 67

The sputum samples were collected in PBS were centrifuged at 1957 x g for 10 min. Supernatant was 68 decanted and the pellet was resuspended in 0.5 ml PBS and stored at -70oC till further processing. The 69 positive control consisted of relevant purified mycoplasma DNA. The extraction of DNA was done using the 70 organic methods described by Das et al [5]. A 543 bp section of the P1 protein gene of M.pneumoniae 71 was selected for amplification. The primers (Bangalore Genei Pvt. Ltd., Banglore, India) were: Primer1: 72 5'CAAGCCAAACACGAGCTCCGGCC-3', which is complimentary to the P1 gene negative strand residues 73 3666-3688, and Primer 2 : 5'CCAGTGTCAGCTGTTTGTCCTTCCCC-3', which is complimentary to the P1 74 gene positive strand residues 4208-4183. 75

Amplification was done according to the guidelines of Taq DNA polymerase (Bangalore Genei Pvt. Ltd., Banglore, India). Amplified PCR products were subjected to electrophoresis on 3 ethidium bromide stained agarose gel, along with a molecular weight marker. A mixture of 2 µl genomic DNA, 2 µl of 6 X BPB and 8 µl of distilled water was loaded into the 1 per cent agarose gel. The electrophoresis was carried out at a constant voltage of 50 V for 1 h, and a band at 543 bp was taken to be a positive result. The PCR of those patients whose culture and serology was positive was carried out.

#### 82 3 III. Results

Table 1 represents the age wise distribution of study subjects. The total number of study subjects was 286. The total number of male subjects were 207 (72.4 %) while 79 (27.6 %) were females. Highest number of subject's i.e. 32.9 % subjects were less than 30 years while second highest number i.e. 30.4 % of study subjects was more than 45 years. Table 2 Gender wise distribution of study subjects. Table 3 shows the test result by different diagnosis technique of mycoplasma pneumonia. Out of 286 patients 168 (58.7 %) samples were found positive in culture and 98 (34.3%) samples were found to be positive in serology test. PCR testing shows only 80 (28 %) samples were found to be positive.

#### <sup>90</sup> 4 b) Sample size calculation

Sample size was calculated by the sample size calculation formula for sing proportion by n=4pq/d 2, Where n: sample size, p: prevalence q: 1-p and d is specified absolute precision by assuming prevalence 21 %, with specified absolute precision 0.06 and 10 % data loss, be. Calculated sample size is 260. Adding 10% non-response, the final sample size is 286.

Sample size is 260. Adding 10% non-response, the final sample size is 286.

i. Inclusion criteria Patients clinically diagnosed clinical and radiological proven of atypical pneumonia will be included in the study with, 1. Community acquired pneumonia (CAP): 2. Presence of a new pulmonary

infiltrate/ shadow on chest X-ray suggestive of pneumonia at/ within 24 h of hospitalization.
 Patient residing
 in community.

ii. Exclusion criteria 1. Hospital acquired pneumonia i.e. pneumonia that developed 72 h after hospitalization
 or within 7 days of discharge. 2. Pulmonary shadow due to a cause other than pneumonia. 3. The serious

patients having other disease with atypical pneumonia will be excluded A written informed consent was taken
 from the parent/legal guardian of the children before them being enrolled in the study.

Clinical data from the patients were collected using a questionnaire developed and validated and a detailed examination was performed. Routine laboratory investigations were done in all subjects. In the present study culture, serology and PCR technique is used to diagnose the mycoplasma pneumonia.

## <sup>107</sup> 5 IV. Discussion

A variety of techniques are used to assess M. pneumoniae, each with different advantages and disadvantages. In 108 this study, PCR, ELISA, and culture methods were employed for the detection of M. pneumoniae infection in 109 286 suspected patients. The culture method for the isolation of M. pneumoniae requires 2-4 weeks, which limits 110 itsclinical usefulness. Moreover, culturing of M. pneumoniae is expensive and time-consuming (7-10). Serological 111 methods are more extensively used than culture, because they are easier to carry out and more affordable (11-112 13). However, they are generally nonspecific, retrospective, and need 2 samples for titration 7. It should be noted 113 that in our study, the most reliable result was obtained by the PCR method, which proved to be highly sensitive, 114 specific, and faster than other methods. The specificity of the culture method was 100%, while its sensitivity 115 barely reached 33%, relative to the results of the PCR method as a gold standard. All of the culture and IgM 116 ELISA test positive patients were PCR-positive, too. The PCR method is more sensitive and is the gold standard 117 currently being used for diagnosis of this organism in some laboratories 14 118

#### <sup>119</sup> 6 V. Conclusion

In the present study it is concluded that only one technique may not be sufficient to diagnose the mycoplasma pneumonia as these techniques do not show higher sensitivity and specificity as many results suggest the same [6]. However, serology and culture is done commonly.

### <sup>123</sup> 7 VI. Acknowledgment

124 The authors acknowledge the help provided by various faculties, technicians and paramedical staffs of Career

Institute of Medical Sciences, Lucknow, for providing patient samples. Authors would like to acknowledge the Dean/Director of the institute to provide great support.




Figure 1: Figure 3 a

126

 $<sup>^1 \</sup>rm Volume ~XV$  Issue IV Version IYear 2015© 2015 Global Journals Inc. (US)

#### 1

Age Group (years)	Sample N $(\%)$	
<3	15	5.2%
3-5	21	7.3%
6-10	33	11.5%
11-15	19	6.6~%
16-30	94	32.9~%
31-45	87	30.4%
46-60	9	3.1%
>60	8	28~%



 $\mathbf{2}$ 

Gender	Ν	%
Male	207	72.4
Female	79	27.6
	Figure 2	

Figure 3: Table 2 :

#### 3

Test Result	Culture	Serology	PCR
	(n=286)	(n=286)	(n=286)
Positive Result	168(58.7%)	98~(34.3%)	80(28%)
Negative result	118(41.3%)	188~(65.7%)	206(72%)

Figure 4: Table 3 :

- 127 [Waites ()], Ken B Waites, DeborahF. Talkington Clin. Microbiol. Rev. October 2004. 17 (4) p. .
- 128 [(October 200)], 10.1128/CMR.17.4.697-728.2004. October 200.
- [Talkington et al. ()] 'Analysis of Eight Commercial Enzyme Immunoassay Tests for Detection of Antibodies to
  Mycoplasma pneumoniae in Human Serum'. D F Talkington , S Shott , M T Fallon , S B Schwartz , W L
  Thacker . doi: 10. 1128/CDLI.11.5.862-867. *Clinical and Diagnostic Laboratory Immunology* 2004. 2004. 11
  (5) p. .
- 133 [Shin et al. ()] 'Crystal structure of the DUF16 domain of MPN010 from Mycoplasma pneumoniae'. D H Shin
- , J-S Kim, H Yokota, R Kim, Kim S-H. 10.1110/ps.051993506. Protein Science: A Publication of the Protein Society 2006. 15 (4) p. .
- $\label{eq:stars} 136 \quad [{\rm Sasaki\ et\ al.\ } ()] \ `{\rm Epidemiological\ study\ of\ Mycoplasma\ pneumoniae\ infections\ in\ Japan\ based\ on\ PCR-restriction}$
- fragment length polymorphism of the P1 cytadhesin gene'. T Sasaki , T Kenri , N Okazaki , M Iseki , R
   Yamashita , M Shintani . J Clin Microbiol 1996. 34 p. .
- [Atkinson et al. ()] 'Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma
   pneumoniae infections'. T P Atkinson , M F Balish , K B Waites . *FEMS Microbiol Rev* 2008. 32 p. .
- [Beersma et al. ()] 'Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma
   pneumoniae-specific immuneglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard'. M
   F Beersma , K Dirven , A P Van Dam , K E Templeton , E C Claas , H Goossens . J Clin Microbiol 2005.
- 144 43 p. . [ 43 p. ]
- 145 [gnostics Specific and sensitive diagnosis Mycoplasma pneumoniae IgG] http://www.medac.de/medac\_
- international/data/dia gnostics Specific and sensitive diagnosis Mycoplasma pneumoniae IgG, (IgA-,
   IgM-ELISA) (nb)
- [Daxboeck et al. ()] 'Laboratory diagnosis of Mycoplasma pneumoniae infection'. F Daxboeck , R Krause , C
   Wenissch . Clin Microbiol Infect 2003. 9 p. .
- [Waites and Talkington ()] 'Mycoplasma pneumoniae and its role as a human pathogen'. K B Waites , D F
   Talkington . Clin Microbiol Rev 2004. 17 p. .
- [Zhang et al. ()] 'PCR versus serology for diagnosing Mycoplasma pneumoniae infection: A systematic review
  & metaanalysis'. L Zhang , Z-Y Zong , Y-B Liu , H Ye , X-J Lv . The Indian Journal of Medical Research
  2011. 134 (3) p. .
- [Dunn et al. ()] 'Rapid detection of Mycoplasma pneumoniae IgM antibodies in pediatric patients using ImmunoCard Mycoplasma compared to conventional enzyme immunoassays'. J J Dunn , A K Malan , J Evans
  , C M Litwin . *Eur J Clin Microbiol Infect Dis* 2004. 23 p. .
- [Liu et al. ()] 'Rapid diagnosis of Mycoplasma pneumoniae infection in children by polymerase chain reaction'.
   F C Liu , P Y Chen , F L Huang , C R Tasai , C Y Lwee , L C Wang . J Microbiol Immunol Infect 2007. 40
   p. .
- <sup>161</sup> [Ma et al. ()] 'Rapid Mycoplasma culture for the early diagnosis of Mycoplasma pneumoniae infection'. L D Ma <sup>162</sup> , M Chen , Y Dong , J Fan , L Xia , S Wang . J Clin Lab Anal 2010. 24 p. .
- [Kashyap et al. (2008)] 'Saigal Comparison of PCR, culture & serological tests for the diagnosis of Mycoplasma
   pneumoniae in community-acquired lower respiratory tract infections in children Indian'. Bineeta Kashyap ,
   Surinder Kumar , G R Sethi , \* , B C R Das\*\* & S . J Med Res August 2008. 128 p. .